Decitabine — CPB 0868 | AETNA Coverage Update

Aetna modified CPB 0868 covering decitabine, effective September 26, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0868 governing decitabine coverage under commercial medical plans. This policy covers HCPCS code J0893 (decitabine injection, Sun Pharma, 1 mg) and spans administration codes CPT 96360–96417, across a wide range of oncologic diagnoses including hematologic malignancies, solid tumors, and select lymphomas. If your team handles oncology billing for Aetna commercial plans, this update is in play for your claims.

Quick-Reference Table

Aetna Decitabine Coverage Criteria and Medical Necessity Requirements 2025

The Aetna decitabine coverage policy under CPB 0868 applies to commercial medical plans only. For Medicare patients, Aetna directs billers to separate Medicare Part B criteria — not this bulletin. Keep those populations in separate workflows.

HCPCS code J0893 is the primary billable code under this policy. It covers injection of decitabine manufactured by Sun Pharma, billed per 1 mg. The policy explicitly notes J0893 is not therapeutically equivalent to J0894. If your team has been using J0893 and J0894 interchangeably, stop. Aetna treats them as distinct products with potentially different coverage criteria.

Medical necessity documentation is the core requirement for coverage. Aetna will look for diagnosis-specific clinical criteria to justify each decitabine claim. The 111 ICD-10 diagnosis codes attached to this policy span esophageal cancer (C15.3–C15.9), gastric malignancies (C16.0–C16.9), colon cancer (C18.0–C18.9), melanoma (C43.0–C43.9), endometrial cancer (C54.1), ovarian cancer (C56.1–C56.9), Hodgkin lymphoma (C81.00–C81.9A), and a range of alimentary tract and other cancers. Your diagnosis code must match the covered indications list — a mismatch is a fast path to claim denial.

Prior authorization is standard for oncology drug administration under Aetna commercial plans. Confirm your prior authorization workflow is current for J0893 before submitting claims under the updated policy. If you're not sure whether your authorization criteria align with the September 26, 2025 effective date, call Aetna provider relations before the claim goes out.

The administration codes — CPT 96360 through 96417 — cover the infusion and injection services around decitabine delivery. These are listed as "other CPT codes related to the CPB," meaning they travel with J0893 as the drug code. You don't get reimbursement for the administration if the drug itself isn't covered under a valid medical necessity determination.

Aetna Decitabine Exclusions and Non-Covered Indications

One code in the data stands out as a flag: J9271, the injection code for pembrolizumab (1 mg). It appears in the policy under the group label "Venetoclax — no specific code." That's a confusing pairing.

The real issue here is that pembrolizumab has a distinct coverage context — Aetna covers it with decitabine in the setting of classic Hodgkin lymphoma (ICD-10 C81.00–C81.9A). If you're billing a combination regimen, J9271 isn't covered under CPB 0868 as a standalone decitabine claim. It's referenced in the context of a Venetoclax-related note with no dedicated HCPCS code. That's worth a conversation with your compliance officer if you're billing combination regimens that include pembrolizumab and decitabine for lymphoma patients.

Don't assume that any ICD-10 code appearing in the policy list automatically means "covered for all uses." Aetna ties coverage to specific clinical criteria per indication. A diagnosis of melanoma (C43.x) appearing in the list doesn't mean decitabine is first-line covered for melanoma — it means that combination is addressed somewhere in the bulletin's criteria. Check the full CPB 0868 text at Aetna's provider portal to confirm coverage status for each specific clinical scenario your practice bills.

Coverage Indications at a Glance

Aetna Decitabine Billing Guidelines and Action Items 2025

The September 26, 2025 effective date is already here. These aren't future tasks — they're overdue if you haven't acted yet.

CPT, HCPCS, and ICD-10 Codes for Decitabine Under CPB 0868

HCPCS Codes — Covered When Selection Criteria Are Met

CPT Codes — IV Infusion and Injection Administration

Key ICD-10-CM Diagnosis Codes

Note: The policy references 111 total ICD-10-CM codes. Confirm the full list against the current CPB 0868 document at Aetna's provider portal before finalizing your ICD-10 mapping.